Innoviva Inc Overview
Industry: Biotechnology
Sector: Healthcare
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California. Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluti Read MoreReported Results
What the company reported, with filing details kept small.
Quarterly result summary
Stored reported-result values did not pass automated reconciliation.
What changed
- Open the SEC source filing while these values are reprocessed.
Source review
Mavefund has withheld unreconciled figures from the public page.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
May 06, 2026
SEC filing
8-K
May 06, 2026
SEC filing
10-K/A
Mar 27, 2026
SEC filing
8-K
Feb 25, 2026
Earnings release
Earnings release
Feb 25, 2026
SEC filing
10-K
Feb 25, 2026
SEC filing
FORM 8-K
Nov 05, 2025
Earnings release
EXHIBIT 99.1
Nov 05, 2025
SEC filing
10-Q
Nov 05, 2025
SEC filing
10-Q
Aug 06, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
No qualified company news in the last 14 days
No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.